Stockpolly
Search
Delisting risk
JAGX · NASDAQ · Biotechnology

Jaguar Health (JAGX)

Develops and supplies crofelemer treatments for intestinal failure and diarrhea in people and animals.

$0.7200
Pre-market−0.02 (−2.68%)
At close$0.7398(+1.20%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue3223342333201
Cost of revenue110011111211
Gross profit2222332231190
11910910111110102198
Research & development6344454341443
556667776554
Selling & marketing121222111110
General & administrative445445665444
Other expenses010000000200
Operating income−9−8−8−7−7−8−9−8−7−2010−8
1−2−1−2−3−2−1−3−2−3−1−5
Interest income000000000000
Interest expense101000000010
Other non-operating income001238132915
Income before tax−8−9−9−10−10−10−11−11−10−239−13
Net income from continuing operations−8−9−9−10−10−10−11−11−10−239−13
Other adjustments000001000000
Net income−8−9−9−9−10−10−10−10−10−239−13
EPS, basic−$19,689.00−$6,581.92−$3,049.20−$3,535.11−$920.18−$657.03−$584.44−$358.94−$219.78−$116.40−$13.60−$15.70
EPS, diluted−$19,689.00−$6,581.92−$3,049.20−$3,535.11−$920.18−$657.03−$584.44−$358.94−$219.78−$116.40−$13.60−$15.70
Weighted average shares, basic000000000011
Weighted average shares, diluted000000000011
EBITDA−8−7−8−9−9−16−10−10−9−2910−12
Depreciation & amortization111111111110
EBIT−9−7−9−10−10−16−11−11−10−299−13